

The CLL Sessions: highlights from EHA and ICML 2021
Jul 27, 2021
Experts Paolo Ghia, Susan O'Brien, Lydia Scarfò, and Othman Al-Sawaf review exciting updates in chronic lymphocytic leukemia (CLL) from EHA and ICML 2021. They discuss key clinical trials, second-generation BTKs, fixed-duration therapy, depth of response, stopping treatment, retreatment potential, progression-free survival, VTK inhibitors, akylobrutinib vs. britinib, and different CLL treatment regimens.
Chapters
Transcript
Episode notes
1 2 3 4 5 6
Introduction
00:00 • 3min
Quality and Depth of Response, Possibility of Stopping Treatment
03:15 • 2min
Advantages and Retreatment Potential
04:47 • 8min
Progression-free survival of patients with P53 aberrations and comparison of VTK inhibitors
12:28 • 2min
Comparing the Efficacy and Side Effects of Akylobrutinib and Britinib in CLL Patients
14:36 • 11min
Comparing Different Regimens for CLL Treatment
25:43 • 11min